FilingsTodayBio-Techne
At a glance
Bio-Techne reported 2025 revenue of $1.22B, up 5.2% from $1.16B in 2024. Over 4 years since 2021 ($931M), that is growth of about 7% a year. Operating margin was 8.4%, down from 25.5% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 1 insider reported 0 open-market purchases and 2 sales ($437K). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $320K by Director Amy E. Herr on May 12, 2026.
Bio-Techne filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), shareholder vote results (2), officer or director change (2) and other events (1). The latest officer or director change was reported on Jun 26, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
2 of the 20 investors tracked here held Bio-Techne at the last quarter end, worth $39.7M combined. It is the largest weight for Soros Fund Management (0.6% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Soros Fund Management. Added: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M |
| Diluted EPS | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 |
| Dividend per share | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 |
Fiscal year ends Jun 30 · incorporated in MN
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined